Skip to content

Advertisement

  • Poster presentation
  • Open Access

Complement analysis reveals new biomarkers in patients with juvenile idiopathic arthritis

  • 1,
  • 1 and
  • 1
Pediatric Rheumatology201412 (Suppl 1) :P32

https://doi.org/10.1186/1546-0096-12-S1-P32

  • Published:

Keywords

  • Acute Phase
  • Synovial Fluid
  • Juvenile Idiopathic Arthritis
  • Alternative Pathway
  • Complement System

Introduction

The juvenile idiopathic arthritis is a well researched disease in the group of autoimmunopathies. Beside the deregulation of T-cells and cytokines also the complement system is involved in the pathogenesis of this group of diseases.

Objectives

This prospective longitudinal study investigated the contribution of the complement system in patients with juvenile idiopathic arthritis, using practicable ELISA techniques (Wieslab® screening kit; SC5b9 soluble terminal complement complex ELISA).

Methods

Serum and plasma of the peripheral blood and the synovial fluid were investigated for the activity of the three complement pathways - classical (CP), mannose binding lectin (MBL), and the alternative pathway (AP) and total complement activity by measuring SC5b9. Results where compared to published reference controls and 18 children without activation of inflammation as an age matched control group.

In total 57 samples of peripheral blood (PB) and 8 samples from synovial fluid (SF) from 28 children with JIA were investigated in a longitudinal observation during acute phase and remission.

Results

The screening of complement system showed debasement of the AP (8 of 10) and CP (7 of 10) in patients during acute phase (7 of 10). The SC5b9 measurement showed a significant (p<0.002) higher amount in plasma (3,6AU/ml in median) and serum (31,4AU/ml) during acute phase compared to the control group (serum - 7,72AU/ml and plasma – 1,25AU/ml in median).

Conclusion

In conclusion the study confirmed, that the CP and AP of the complement system are main contributors in the pathogenesis of JIA. Because of significant elevation of SC5b9 in acute phase of JIA, complement blockade with Anti-C5 may be a therapeutically option in the future.

Disclosure of interest

None declared.

Authors’ Affiliations

(1)
Medical University Innsbruck, Innsbruck, Austria

Copyright

© Brunner et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement